Envista (NYSE:NVST) Hits New 12-Month High – Should You Buy?

Envista Holdings Corporation (NYSE:NVST) reached a new 52-week high during trading on Wednesday . The company traded as high as $24.25 and last traded at $24.22, with a volume of 2140295 shares. The stock had previously closed at $23.23.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Envista from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 16th. Stifel Nicolaus set a $25.00 price objective on Envista in a report on Thursday, October 30th. Mizuho set a $19.00 target price on Envista in a report on Monday, November 3rd. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 10th. Finally, Barclays began coverage on Envista in a report on Monday, December 8th. They issued an “overweight” rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Envista has a consensus rating of “Hold” and an average price target of $21.77.

Envista Stock Up 2.2%

The firm has a market capitalization of $4.15 billion, a PE ratio of 280.48, a PEG ratio of 1.10 and a beta of 0.99. The business’s fifty day moving average price is $21.49 and its 200 day moving average price is $20.78. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $669.90 million during the quarter, compared to analysts’ expectations of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the firm earned $0.12 EPS. On average, equities research analysts forecast that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.

Institutional Trading of Envista

Several hedge funds and other institutional investors have recently made changes to their positions in NVST. Farther Finance Advisors LLC increased its position in shares of Envista by 317.6% in the third quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock valued at $27,000 after buying an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Envista by 16,711.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after acquiring an additional 1,504 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after purchasing an additional 1,909 shares in the last quarter. Finally, SJS Investment Consulting Inc. grew its position in shares of Envista by 10,356.5% in the third quarter. SJS Investment Consulting Inc. now owns 2,405 shares of the company’s stock valued at $49,000 after purchasing an additional 2,382 shares during the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.